To: Board of Supervisors
From: Dr. Grant Colfax, Health Services Director
Report Title: Amendment to Purchase Order with CDPH Genetic Disease Screening Program
☒Recommendation of the County Administrator ☐ Recommendation of Board Committee
RECOMMENDATIONS:
APPROVE and AUTHORIZE the Purchasing Agent, or designee, to execute on behalf of the Health Services Director, an amendment to purchase order #27755 with the California Department of Public Health (CDPH) Genetic Disease Screening Program, to increase the payment limit by $200,000 to a new amount not to exceed $1,200,000 for newborn genetic screening tests performed at the Contra Costa Regional Medical Center (CCRMC) Clinical Laboratory, with no change in the original term ending June 30, 2026.
FISCAL IMPACT:
Approval of this action will result in expenditures of up to $1,200,000 over the three-year period between July 1, 2023, through June 30, 2026, and will be funded by Hospital Enterprise Fund I.
BACKGROUND:
The California Newborn Screening Program (NBS) is a public health program that screens all babies for eighty (80) disorders, both genetic and congenital. All babies born in the State of California are required to be screened after birth. The goal of the program is to identify babies with these disorders early, in order to provide treatment right away. The newborn screening is completed by taking a sample of the newborn’s blood within twelve (12) to forty-eight (48) hours of life. California Health and Safety Code 125000 regulates that all hospitals provide Genetic Screening Program testing. Billing is directed by CDPH which provides accreditation for CCRMC and the Clinical Laboratory.
On August 16, 2022, the Board of Supervisors approved agenda item C.37 to execute a purchase order #26277 with the CDPH Genetic Disease Screening Program in an amount not exceed $325,000 for newborn genetic screening tests performed at CCRMC, for the period of July 1, 2022 through June 30, 2023.
On April 18, 2023, the Board of Supervisors approved agenda item C.67 to execute a purchase order #27755 with the CDPH Genetic Disease Screening Program in an amount not to exceed $1,000,000 for newborn genetic screening tests performed at CCRMC, for the period of July 1, 2023 through June 30, 2026.
On March 23, 2026 the Purchasing Agent approved the continued use of CDPH Genetic Disease Screening Program. Approval of this action will support CCRMC’s ability to continue compliance with the requirements and goals of the NBS Program and allow CDPH to continue providing newborn genetic screening tests to CCRMC through June 30, 2026.
CONSEQUENCE OF NEGATIVE ACTION:
If this action is not approved, it will affect CCRMC’s ability to pay timely invoices for the genetic screening that is required by the State of California.